Search results
Showing 646 to 660 of 2208 results for guidelines
Awaiting development Reference number: GID-TA10438 Expected publication date: TBC
Semaglutide for treating type 2 diabetes in people 10 to 17 years [TSID12249]
Topic prioritisation
Dapagliflozin in combination therapy for treating type 2 diabetes (TA288)
Evidence-based recommendations on dapagliflozin (Forxiga) given with other drugs for treating type 2 diabetes in adults.
Vitamin D: supplement use in specific population groups (PH56)
This guideline covers vitamin D supplement use. It aims to prevent vitamin D deficiency among specific population groups including infants and children aged under 4, pregnant and breastfeeding women, particularly teenagers and young women, people over 65, people who have low or no exposure to the sun and people with dark skin.
How voluntary and community sector organisations can help us develop guidance
How voluntary and community sector (VCS) organisations can help NICE develop guidance
This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.
Eculizumab for treating atypical haemolytic uraemic syndrome (HST1)
Evidence-based recommendations on eculizumab (Soliris) for treating atypical haemolytic uraemic syndrome in adults and children.
Good practice guidance – Integrated process statement (PMG12)
This process statement has been produced to explain how good practice guidance is developed. It provides an overview of the key process principles and describes all stages of the development of good practice guidance
27 May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with COVID-19 see our guideline on managing COVID-19.
Our guidance is developed by independent committees, including professionals and lay members, and consulted on by stakeholders.
Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA393)
Evidence-based recommendations on alirocumab (Praluent) for treating primary hypercholesterolaemia or mixed dyslipidaemia in adults.
Antimicrobial prescribing: delafloxacin for community-acquired pneumonia (ES37)
Summary of the evidence on delafloxacin for community-acquired pneumonia in adults